Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of THDBH120 in Chinese Patients with Type 2 Diabetes
NCT07020949Phase 1Completed
- Sponsor
- Tonghua Dongbao
- Start
- Jun 2024
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing THDBH120 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s) at 78 days. Started Jun 2024; status: completed.
02
Drugs
THDBH120
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07020949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020949.